Beam Therapeutics
Beam Therapeutics Inc is an American clinical-stage biotechnology company focused on developing precision genetic medicines utilizing base editing technology. The company develops base editing therapies to make single-base changes in genomic DNA without double-stranded breaks, advancing clinical candidates for sickle cell disease, beta-thalassemia, and alpha-1 antitrypsin deficiency. Revenue is generated from strategic research collaboration agreements, technology licensing fees, and development milestone payments from global biopharmaceutical partners. Core end markets serve hematology centers, genetic disease clinics, and specialized clinical research institutions globally. Beam Therapeutics holds a pioneering position in the biotechnology sector as a premier developer of precise base editing genetic medicine platforms. The company is headquartered in Cambridge, Massachusetts, and its common stock trades on the Nasdaq Global Select Market.
4 of the funds FundTelligence covers report a position in Beam Therapeutics.
- Legal name
- Beam Therapeutics Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 4
- Exposure themes
- Gene Editing, Genetic Medicine, Precision Medicine & Genomics
Funds holding Beam Therapeutics
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.18 % (full portfolio disclosed, October 2026)
- Mercer Global Small Cap Equity Fund — Mercer · 0.13 % (full portfolio disclosed, December 2025)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.04 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.03 % (partially disclosed portfolio, June 2026)